Molecular Classification of Fever of Unknown Origin: A Contemporary Review

Abstract

Fever of Unknown Origin (FUO) remains a challenging clinical dilemma, often requiring exhaustive diagnostic efforts. Recent advances in molecular diagnostics have revolutionized the categorization and management of FUO, enabling a more precise etiological diagnosis and targeted therapy. This review provides a comprehensive overview of the molecular classification of FUO, integrating current evidence, clinical guidelines, and emerging technologies. The article aims to equip clinicians with actionable knowledge on the molecular underpinnings, diagnostic approaches, and therapeutic implications of FUO.

Introduction

Fever of Unknown Origin, traditionally defined as a temperature >38.3°C on several occasions lasting for more than three weeks with no identified cause after one week of inpatient investigation, has evolved in concept with advances in diagnostic technologies. The molecular era has introduced new paradigms in the classification and management of FUO, with pathogenesis-driven approaches supplanting traditional empiric strategies. Understanding the molecular mechanisms underlying FUO is crucial for optimizing diagnostic yield and therapeutic outcomes in both adult and pediatric populations.

Epidemiology / Disease Burden

FUO accounts for approximately 2-3% of all hospital admissions in internal medicine and infectious disease units. Despite improvements in healthcare infrastructure and access to diagnostics, up to 25-30% of FUO cases remain undiagnosed. The etiological spectrum varies geographically, with infectious, neoplastic, and non-infectious inflammatory diseases being predominant causes. The advent of molecular techniques has not only increased the diagnostic rate but also altered the epidemiological landscape, revealing previously unrecognized infectious agents and rare genetic disorders.

Pathophysiology

The molecular pathophysiology of FUO is heterogeneous, reflecting its diverse etiologies. Infectious causes may involve pathogen-specific nucleic acid sequences, while autoimmune or autoinflammatory conditions often demonstrate specific gene expression profiles and cytokine signatures. Neoplastic fevers are linked to tumor-derived pyrogens, oncogene mutations, and molecular markers associated with paraneoplastic syndromes. Recent studies utilizing transcriptomics, proteomics, and metabolomics have uncovered unique molecular fingerprints that distinguish between infectious, inflammatory, and malignant causes, providing mechanistic insights and facilitating precision medicine approaches.

Risk Factors

Risk factors for FUO include advanced age, immunosuppression, chronic comorbidities (such as diabetes mellitus and chronic kidney disease), recent travel to endemic regions, and underlying autoimmune predisposition. Genetic susceptibility, as evidenced by certain single nucleotide polymorphisms (SNPs) in immune response genes (e.g., NOD2, MEFV), has emerged as a critical determinant of FUO in the molecular era. Hospital-acquired FUO is increasingly recognized, particularly among transplant recipients and oncology patients, often involving multidrug-resistant organisms or atypical pathogens.

Clinical Features

Clinically, FUO presents with persistent fever unresponsive to empirical therapy, often accompanied by constitutional symptoms such as malaise, weight loss, and night sweats. Physical findings are typically non-specific, necessitating a high index of suspicion for subtle signs of systemic disease. Molecular subtypes may exhibit distinct clinical phenotypes for example, periodic fevers associated with hereditary autoinflammatory syndromes (e.g., Familial Mediterranean Fever) or relapsing fever patterns in certain viral infections. Recognizing these patterns is essential for directing molecular investigations and optimizing diagnostic yield.

Diagnosis

The diagnostic approach to FUO has been transformed by the integration of molecular technologies, including multiplex polymerase chain reaction (PCR), next-generation sequencing (NGS), and metagenomic analyses. These tools allow for the detection of elusive pathogens, identification of rare genetic mutations, and characterization of immune signatures. Molecular classification of FUO now incorporates pathogen genomics, host transcriptomics, and proteomic profiling to stratify patients into diagnostic categories. Tissue biopsies, when indicated, benefit from immunohistochemical and molecular analyses to uncover occult malignancies or granulomatous diseases. The adoption of diagnostic algorithms incorporating molecular tools has significantly reduced the proportion of idiopathic FUO cases.

Treatment & Management

Management of FUO is guided by the underlying etiology, with molecular findings informing targeted therapy. Infectious causes require pathogen-directed antimicrobial therapy, while autoimmune and autoinflammatory diseases benefit from immunomodulatory agents tailored to specific molecular pathways (e.g., IL-1 inhibitors in cryopyrin-associated periodic syndromes). In neoplastic FUO, oncological management is driven by molecular characterization of the tumor. Supportive care remains paramount in undiagnosed cases, with close monitoring for emerging clinical or molecular clues. Multidisciplinary collaboration and individualized care plans are essential, especially in complex or refractory cases.

Recent Advances / Emerging Therapies

Emerging molecular technologies continue to reshape the diagnostic and therapeutic landscape of FUO. Whole exome and genome sequencing have enabled the identification of novel monogenic autoinflammatory syndromes, expanding the spectrum of hereditary fever disorders. Metagenomic next-generation sequencing of blood and tissue samples has facilitated the detection of fastidious and novel pathogens. Machine learning algorithms applied to molecular datasets are showing promise in predicting etiology and clinical outcomes. Targeted biologic therapies, such as JAK inhibitors and monoclonal antibodies against specific cytokines, represent a new frontier in the treatment of molecularly defined FUO subtypes.

Guideline Recommendations

International guidelines now emphasize a tiered, molecularly informed approach to FUO. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Infectious Diseases Society of America (IDSA) advocate for early use of multiplex molecular assays and NGS in select cases, particularly when conventional diagnostics fail. Genetic testing is recommended in patients with recurrent or familial fever syndromes. Guidelines underscore the importance of integrating molecular data with clinical assessment to avoid unnecessary empiric therapy, reduce diagnostic delays, and improve patient outcomes.

Conclusion

The molecular classification of FUO represents a paradigm shift in the evaluation and management of prolonged, unexplained fevers. By leveraging advanced molecular diagnostics and integrating clinical, genomic, and immunologic data, clinicians can achieve higher diagnostic accuracy and tailor treatments to the underlying pathophysiology. Continued research and adoption of molecular technologies hold promise for reducing the burden of idiopathic FUO and enhancing patient care in this complex clinical entity.